Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|December 15, 2011
ACT Presents the 17th Annual Corporate Profiles—CROs and Product/Service Providers Directory
Advertisement
17th Annual Corporate Profiles
Click on any logo below to be directed to Corporate Profiles prepared by leading companies in the clinical trials industry. We hope you find this resource most useful and informative.
ACM Global
Actigraph
Advanced Clinical
Almac
Anderson
Aptiv Solutions
Asaman
AtCor
Barnett
Bioclinica
Biomedical Systems
Catalent Pharma Solutions
Clinical Financial Services
Clinical Resource Network
Comprehensive Clinical Development
Corporate Translations
Crucial
DaVita Clinical Research
ERT
Ethical & Independent Review Services
Eurofins
Evaluate Pharma
Exco InTouch Ltd
ExecuPharm, Inc.
ExL Pharma
Firecrest
Global Care Clinical Trials
Marken
Medical Research Network (MRN)
Medpace
Octagon
Outcome
PAREXEL International
PCM Trials
Perceptive Informatics
PharmaNet
PPD
PRA International
REGISTRAT-MAPI
SAS
Sparta Systems Inc.
Spectra Clinical Research
Vetter Pharma International
Worldwide Clinical Trials
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
Where AI Governance in Clinical Development Falls Short
5